

Serial No. 09/865,637  
Group Art Unit: 1648

2

## Amendments to the Claims

### Claims 1-12 (cancelled)

13. (currently amended) A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection, comprising administering to a patient a pharmaceutical composition comprising an isolated Varicella Zoster Virus IE63 protein ~~or a fragment or derivative thereof~~ and a pharmaceutically acceptable excipient, wherein the composition induces ~~an immunoprotective~~ a humoral or cellular immune response without significant, adverse side effects.

14. (currently amended) A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection, comprising administering to a patient a pharmaceutical composition comprising an isolated nucleic acid encoding IE63 ~~or a fragment or derivative thereof~~, wherein the composition induces ~~an immunoprotective~~ a humoral or cellular immune response without significant, adverse side effects.

15. (previously added) A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 13, additionally comprising other VZV antigens.

16. (currently amended) A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 15, wherein the other VZV antigens are selected from the group, gpl, gpII, gpIII, gpIV, gpV or IE62 or ~~immunological functional derivative~~ anchorless derivatives thereof.

17. (previously added) A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 13, additionally comprising an adjuvant.

18. (previously added) A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 17, wherein the adjuvant preferentially induces a TH1 response.

Serial No. 09/865,637  
Group Art Unit: 1648

3

19. (previously added) A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 18, wherein the antigen is presented as an oil in water emulsion together with QS21 and 3D-MPL.

20. (currently amended) A method of producing a pharmaceutical composition comprising an isolated Varicella Zoster virus IE63 protein ~~or fragment or derivative thereof~~, or an isolated nucleic acid encoding a Varicella Zoster virus IE63 protein ~~or fragment or derivative thereof~~, comprising mixing said protein ~~or fragment or derivative thereof~~ or said nucleic acid with a pharmaceutically acceptable excipient.

21. (previously added) A method as claimed in claim 20, wherein the excipient comprises an adjuvant.

D